恒瑞医药：注射用HRS-4029获批临床试验

Core Viewpoint - Heng Rui Medicine's subsidiary has received approval for clinical trials of a new neuroprotective agent, HRS-4029, aimed at treating acute ischemic stroke [1] Company Summary - Heng Rui Medicine's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., and Beijing Shengdi Pharmaceutical Co., Ltd. have recently received the Drug Clinical Trial Approval Notice from the National Medical Products Administration [1] - HRS-4029 is a novel neuroprotective agent designed to alleviate excitotoxicity and is intended for the treatment of acute ischemic stroke [1]